Abstract:Objective To evaluate the risk factors of acute-phase reaction (APR)following the first-dose administration of zoledronic acid in osteoporotic patients. Methods The documents of the observational studies about risk factors of APR following the first-dose administration of zoledronic acid in osteoporotic patients were searched from correlative data base until July,2017. The quality of the literature enrolled into the Meta-analysis was evaluated by Newcastle-Ottawa Scale (NOS),and then Meta-analysis was conducted using RevMan 5. 3 software. The effective measurements were expressed as adds ratio (OR) or difference in means (MD)and 95％ confidence interval (CI). Results A total of 17 studies involving 1981 patients with osteoporotic and having the first-dose administration of zoledronic acid were enrolled into the Meta-analysis. Nine hundred and seventy-nine patients had APR (APR + group)and 1002 patients without APR (APR - group). The scores of NOS in 17 articles were all greater than or equal to 6. The results of Meta-analysis showed that the patients in the APR(+)group were significantly younger then those in the APR(-)group (MD = - 3. 27,95％ CI:- 4. 54- - 2. 01,P < 0. 00001). The incidence rate of APR in the patients who had the history of administration of nitrogenous bisphosphonates (NBP)were lower than those without history of administration of NBP,and the difference was statistically significant (OR =0. 27,95％ CI:0. 17-0. 41,P < 0. 00001). The incidence rate of APR in the patients having the history of fracture were higher than those without history of fracture,and the difference was statistically significant (OR =2. 31,95％ CI:1. 29-4. 13,P = 0. 005). The incidence rate of APR in the patients who had analgesic-antipyretic preventability treatment were lower than those who had no analgesic-antipyretic preventability treatment,and the difference was statistically significant (OR = 0. 14,95％ CI:0. 05-0. 37,P < 0. 0001). There were no statistical correlation between the patients′ body mass index,creatinine clearance,prior calcium usage,prior calcitriol usage,sex and APR. Conclusion Low age and the history of fracture are risk factors of APR,while the histories of administration of NBP and analgesic-antipyretic preventability are the protective factors of decreasing APR.

Novel combined pharmacological strategy to alleviate acute phase response following zoledronic acid treatment

Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion

Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study

Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial

[Phase III Clinical Study of Zoledronic Acid in the Treatment of Pain Induced by Bone Metastasis from Solid Tumor or Multiple Myeloma].

Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials

Reducing Re-fractures Post Percutaneous Kyphoplasty: The Impact of Zoledronic Acid with Calcium and Vitamin D3 in Osteoporotic Patients

How zoledronic acid improves osteoporosis by acting on osteoclasts

Change in body temperature, not acute-phase reaction, predict anti-Osteoporosis efficacy after the first administration of Zoledronic acid: a prospective observational cohort study

Does Zoledronic Acid Provide a Good Clinical Outcome in Patients With Chronic Back Pain Associated With Vertebral Osteoporosis?

Zoledronic acid relieves steroid-induced avascular necrosis of femoral head via inhibiting FOXD3 mediated ANXA2 transcriptional activation

Risk factors of acute-phase reaction following the first-dose administration of zoledronic acid in osteoporotic patients:a Meta-analysis

Multicenter Study on Observation of Acute-phase Responses after Infusion of Zoledronic Acid 5 Mg in Chinese Women with Postmenopausal Osteoporosis

Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures

Observation of the efficacy and safety of zoledronic and in postmenopausal osteoporosis

Risk factors and measures of acute-phase reactions caused by zoledronic acid injection for treating osteoporosis

The effect of Zoledronic acid on pain and balance in women with postmenopausal osteoporosis

The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients

Acid Neutralization and Immune Regulation by Calcium–Aluminum-Layered Double Hydroxide for Osteoporosis Reversion

Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer

Zoledronic Acid Increases Bone Mineral Density and Improves Health-Related Quality of Life over Two Years of Treatment in Chinese Women with Postmenopausal Osteoporosis.